Basilea Pharmaceutica
PharmaBasel, Switzerland, Switzerland · Est. 2000 · 630 employees
Basilea Pharmaceutica is a Swiss biopharmaceutical company focused on developing and commercializing innovative drugs for oncology and infectious diseases.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
15
Indications↗
Distinct diseases across all programs
58
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Approved1
Phase 33
Phase 21
Phase 13
Preclinical1
By Therapeutic Area
top 4
Infectious Disease
330%
Metabolic & Endocrine
110%
Respiratory
110%
Oncology
110%
R&D Momentum
23/100
Pipeline Velocity
6/100
Trial Completion Rate
87/100
Pipeline Concentration
28/100
Pipeline Freshness
87/100
Strategic Signals
- ↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Earlier
Aug 26, 2025TrialA Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.
Apr 14, 2025TrialA Study of Fosmanogepix in Healthy Adult Chinese Subjects
Jan 17, 2025TrialA Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin
Dec 11, 2024TrialA Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
Nov 4, 2024TrialPlasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Male and Female Participants 18 to ≤55 Years of Age
Aug 6, 2023TrialLate-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
Oct 31, 2022TrialA Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
4 more events
Oct 12, 2022TrialCeftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
Sep 13, 2022TrialFood Effect on Ceftibuten/VNRX-7145 in Healthy Participants
Jun 8, 2021TrialVNRX-7145 Drug-Drug Interaction in Healthy Adult Volunteers
Mar 2, 2021TrialA Bioequivalence Study of APX001 High-load and Low-load Tablets
Details
Company Info
Company Overview
—
Mkt Cap
$300.0M
Revenue
—
Cash
CEOJemiljaren Mahmood
Founded2000
Employees630
HQBasel, Switzerland, Switzerland
Websitebasilea.com
LinkedInCompany Page
Therapeutic Focus
OncologyBacterial infectionsInvasive fungal infections
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Infectious Disease
Infectious Disease
Aspergillosis
CancidasApproved
Candidiasis
CancidasApproved
fosmanogepixPhase 3
Candidiasis, Invasive
CancidasApproved
Pyelonephritis
CedaxPhase 3
Respiratory
Unknown / Other
Candidemia
CancidasPhase 3
Liver Failure
CancidasApproved
Liver Transplant
CancidasPhase 2
Showing 15 of 18 programs
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)